A. Drilon

Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis

BackgroundNeurotrophic tyrosine receptor kinase ( NTRK ) gene fusions are oncogenic drivers in various tumour types. Larotrectinib is a first-in-class, highly selective, central nervous s...

T. Andre ;

D. Hong ;

J. Deeken ;

A. Italiano ;

T. Liu ;

D. Burcoveanu ;

R. Norenberg ;

C. Mussi ;

R. Xu ;

A. Drilon ;

Liang Shen , PhD;

06/25/2023

Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An expanded dataset

Background Neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions are oncogenic drivers in various tumour types. Larotrectinib is a first-in-class, highly selective tropomyosin rece...

Jordan D. Berlin ;

C. Mussi ;

D. Oh ;

Serge Leyvraz ;

A. Drilon ;

Maria de Miguel ;

Yongmei Liu ;

Marc Fellous ;

Lin Shen ;

Thierry André , MD;

Elena Garralda ;

Aitana Ferrandiz ;